Immuno-Biological Laboratories Co (TSE:4570) Total Liabilities: 円312 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4570 Immuno-Biological Laboratories Co Ltd TSE:4570
58 GF Score
Price 円994.00
GF Value 円578.92
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Immuno-Biological Laboratories Co Total Liabilities?

Immuno-Biological Laboratories Co TSE:4570 -0.60% 58 Total Liabilities is 円312 Mil as of Mar. 2026. GuruFocus rates TSE:4570 with a GF Score™ of 58/100 and a GF Value™ of 円578.92 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Immuno-Biological Laboratories Co's Total Liabilities for the quarter that ended in Mar. 2026 was 円312 Mil.

Immuno-Biological Laboratories Co's quarterly Total Liabilities declined from Mar. 2025 (円331.03 Mil) to Sep. 2025 (円309.76 Mil) but then increased from Sep. 2025 (円309.76 Mil) to Mar. 2026 (円311.75 Mil).

Immuno-Biological Laboratories Co's annual Total Liabilities declined from Mar. 2024 (円353.27 Mil) to Mar. 2025 (円331.03 Mil) and declined from Mar. 2025 (円331.03 Mil) to Mar. 2026 (円311.75 Mil).

Immuno-Biological Laboratories Co Total Liabilities Historical Data

* Premium members only.

The historical data trend for Immuno-Biological Laboratories Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immuno-Biological Laboratories Co Total Liabilities Chart

Immuno-Biological Laboratories Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 336.99 355.72 353.27 331.03 311.75

Immuno-Biological Laboratories Co Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 353.27 308.77 331.03 309.76 311.75
TSE:4570
58GF Score
Immuno-Biological Laboratories Co Ltd TSE:4570
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Immuno-Biological Laboratories Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Immuno-Biological Laboratories Co's Total Liabilities for the fiscal year that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=276.194+(18.674+3.773
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+13.106+0)
=312

Total Liabilities=Total Assets (A: Mar. 2026 )-Total Equity (A: Mar. 2026 )
=2155.121-1843.374
=312

Immuno-Biological Laboratories Co's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=276.194+(18.674+3.773
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+13.106+0)
=312

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=2155.121-1843.374
=312

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of 円312 Mil mean?
Immuno-Biological Laboratories Co (TSE:4570) has a Total Liabilities of 円312 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Immuno-Biological Laboratories Co and its competitors.
Is Immuno-Biological Laboratories Co's Total Liabilities too high?
Immuno-Biological Laboratories Co's current Total Liabilities is 円312 Mil. Overall, Immuno-Biological Laboratories Co has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Immuno-Biological Laboratories Co's Total Liabilities compare to VRTX and REGN?
Immuno-Biological Laboratories Co's Total Liabilities of 円312 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Immuno-Biological Laboratories Co and its competitors. Immuno-Biological Laboratories Co's current Total Liabilities is 円312 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immuno-Biological Laboratories Co stock overvalued right now?
Based on GuruFocus' analysis, Immuno-Biological Laboratories Co (TSE:4570) is currently considered Significantly Overvalued. The stock's GF Value™ is 円578.92, compared to a current price of 円994.00 — trading 71.7% above its estimated fair value. The current Total Liabilities is 円312 Mil. Immuno-Biological Laboratories Co's overall GF Score™ is 58/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Immuno-Biological Laboratories Co (TSE:4570), the current Total Liabilities is 円312 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Immuno-Biological Laboratories Co (TSE:4570) Overvalued in 2026?

Based on GuruFocus' analysis, Immuno-Biological Laboratories Co stock appears to be overvalued. The current stock price of 円994.00 is trading 71.7% above its estimated GF Value™ of 円578.92. GuruFocus considers Immuno-Biological Laboratories Co to be Significantly Overvalued.

Key valuation signals for TSE:4570:

  • Total Liabilities: 円312 Mil
  • GF Value™: 円578.92 vs. price of 円994.00 (71.7% above fair value)
  • GF Score™: 58/100 with 2 warning signs

No single metric tells the full story. See the TSE:4570 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Immuno-Biological Laboratories Co Business Description

Address 1091-1 Naka Aza-Higashida, Gunma, Fujioka, JPN, 375-0005
Immuno-Biological Laboratories Co Ltd focuses on research and development. It researches, develops, manufacture and supplies various immunological research reagents, and customized services. It is engaged in research and development of materials used in diagnostic products and valuable seeds and technology for protein production using transgenic silkworm cocoons, which make it possible to create valuable proteins as well as antibodies. It works on clinical reagents for cancer research. Its research scientists are producing inflammatory cytokines, growth factors & antibodies for use against these cancers.
58GF Score

Get the complete analysis for TSE:4570

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円994.00
Price
円578.92
GF Value